NCT01714297

Brief Summary

The purpose of this study is to determine if there are differences in clinical events, i.e bleeding with associated morbidity, if thromboprophylaxis with LMWH (Low Molecular Weight Heparin) is initiated before or after surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Jan 2008

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2008

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2008

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2009

Completed
3.6 years until next milestone

First Submitted

Initial submission to the registry

October 23, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 25, 2012

Completed
Last Updated

December 10, 2012

Status Verified

December 1, 2012

Enrollment Period

5 months

First QC Date

October 23, 2012

Last Update Submit

December 7, 2012

Conditions

Keywords

cemented total hip arthroplastyblood losswound dischargethromboprophylaxisbiomarkers

Outcome Measures

Primary Outcomes (1)

  • total blood loss

    measured blood loss during surgery and in wound drains

    during and after surgery

Secondary Outcomes (3)

  • transfusion requirements

    during and after surgery

  • incidence of bleeding events

    during and after surgery

  • other complications

    during and after surgery

Study Arms (2)

dalteparin 5000IU s.c.

ACTIVE COMPARATOR

5000IU dalteparin s.c. injected the evening before cemented total hip arthroplasty

Drug: dalteparin 5000 IU s.c.

saline

PLACEBO COMPARATOR

Syringes of Saline with the same volume as in the dalteparin injections are injected the evenings before total hip arthroplasty. Dalteparin 5000IU are injected 6 hours after surgery and the concomitant 33 days

Drug: dalteparin 5000 IU s.c.

Interventions

All patients receive injections with either 5000IU dalteparin or saline in the same volume the evening before surgery. All patients receive 5000IU dalteparin 6 hours after surgery and every day from day 2 until day 35.

Also known as: Fragmin
dalteparin 5000IU s.c.saline

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients 50 years or older undergoing cemented total hip arthroplasty for primary osteoarthritis

You may not qualify if:

  • allergy to Low-Molecular-Weight -Heparin
  • bleeding disorders
  • renal failure
  • hepatic disease
  • active treatment for malignancy
  • history of deep venous thrombosis or pulmonary embolism
  • major operations,trauma,stroke or cardiac infarction the last 3 months before surgery.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Martina Hansen's Hospital

Sandvika, Gjettum, 1346, Norway

Location

Related Publications (1)

  • Borgen PO, Dahl OE, Reikeras O. Blood loss in cemented THA is not reduced with postoperative versus preoperative start of thromboprophylaxis. Clin Orthop Relat Res. 2012 Sep;470(9):2591-8. doi: 10.1007/s11999-012-2320-9. Epub 2012 Apr 3.

MeSH Terms

Conditions

InfectionsHemorrhage

Interventions

Dalteparin

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Heparin, Low-Molecular-WeightHeparinGlycosaminoglycansPolysaccharidesCarbohydrates

Study Officials

  • Olav Reikeras, MD, Phd

    Oslo University Hospital

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD.

Study Record Dates

First Submitted

October 23, 2012

First Posted

October 25, 2012

Study Start

January 1, 2008

Primary Completion

June 1, 2008

Study Completion

April 1, 2009

Last Updated

December 10, 2012

Record last verified: 2012-12

Locations